Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.42 |
| ▸ | NPY1R | P25929 | 8/20 | 0.42 |
| ▸ | NPY2R | P49146 | 6/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.42 |
| ▸ | IL1RN | P18510 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21135936 | 0.84 | — | — | |
| SCHEMBL21135937 | 0.83 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RIL1RN | |
| SCHEMBL21135676 | 0.83 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RIL1RN | |
| SCHEMBL23153688 | 0.80 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL21135807 | 0.77 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RCTSL | |
| SCHEMBL25865417 | 0.71 | OPRK1 (0.51) | NPY4RNPY1RNPY2RNPY5RIL1RN | |
| SCHEMBL21135708 | 0.70 | SLC7A5 (0.39) | — | |
| SCHEMBL23223604 | 0.69 | MMP2 (0.63) | IL1RNERAP2ERAP1CTSL | |
| SCHEMBL30534073 | 0.69 | MMP2 (0.63) | IL1RNERAP2ERAP1CTSL | |
| SCHEMBL23223538 | 0.69 | MMP2 (0.63) | IL1RNERAP2ERAP1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961273-B2 | N-carboxyanhydride-based-scale synthesis of elamipretide | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2021-03-30 | — | — | US | disclosed |
| US-20190202861-A1 | N-CARBOXYANHYDRIDE-BASED-SCALE SYNTHESIS OF ELAMIPRETIDE | STEALTH BIOTHERAPEUTICS INC. | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961273-B2 | N-carboxyanhydride-based-scale synthesis of elamipretide | MTPN, TUFM, PDF | NPY4R 358/4885NPY1R 792/4885NPY2R 1302/4885 |
| US-20190202861-A1 | N-CARBOXYANHYDRIDE-BASED-SCALE SYNTHESIS OF ELAMIPRETIDE | MTPN, TUFM, PDF | NPY4R 358/4885NPY1R 792/4885NPY2R 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.